Edwards Lifesciences shares climbed 6.2% after the company presented new clinical data at the New York Valves conference in late June 2026. The data included baseline results from the PROGRESS trial on moderate aortic stenosis and seven-year durability findings for the SAPIEN 3 valve from the PARTNER 3 study. These results reinforce the case for earlier and less invasive transcatheter aortic valve replacement, a key growth driver for the company. Edwards Lifesciences projects $8.3 billion in revenue and $2.2 billion in earnings by 2029, implying 9.6% annual revenue growth. The stock's fair value is estimated at $96.92, representing a 6% upside from current levels.
Edwards Lifesciences CorpPresented new clinical data from PROGRESS and PARTNER 3 trials, reinforcing TAVR growth driver.